SUMMARY Erythrocytes from 14 patients with homozygous sickle cell anaemia were treated with the calcium ionophore A23187 to induce loss of cellular potassium and water. The dehydrated cells showed a decrease in filterability (loss of deformability) through pores of 5 gm diameter. Oxpentifylline and cetiedil citrate, which preserve erythrocyte cation and water content, had a significant (p < 0-01) protective effect against loss of deformability at a concentration of 1 gmol/l.
The dense erythrocytes in patients with sickle cell anaemia are depleted of potassium' and the associated loss of cell water contributes to their high mean cell haemoglobin concentration (MCHC). 2 4 Increase in MCHC greatly increases the intracellular polymerisation of haemoglobin S (HbS)s so that polymer may form at arterial oxygen tension. 6 It is not known whether sickle cells lose potassium and water by direct leakage through a cell membrane distorted by extended spicules of polymer,7 or by opening the Gardos8 channel in response to transient increases in cytoplasmic calcium before this cation becomes compartmentalised in membrane vesicles.9 Alternatively, young sickle cells that swell in response to a fall in pH at sites of ischaemia may lose potassium and water via the recently described volume sensitive KCI cotransport system.'0" Whatever the cause of their dehydration, the deformability of sickle cells is adversely affected by the increase in MCHC122" and is substantially improved by rehydration.12 14 Oxpentifylline is a dimethyl xanthine derivative that binds reversibly to erythrocyte membranes and has been shown to increase walking distance in patients with atherosclerotic intermittent claudication. '5 We have recently shown that the drug prevents loss of potassium and therefore water from normal (haemoglobin AA) erythrocytes that had been loaded with calcium using the ionophore A23187. 16 The same experimental model has now been used to study the action of oxpentifylline on sickle cells from Accepted for publication 21 December 1987 14 patients with homozygous (SS) sickle cell anaemia. Oxpentifylline was compared, at equimolar concentrations, with the iminoester cetiedil citrate which also changes the cation content of sickle cells by increasing passive influx of sodium or preventing loss of potassium induced by calcium gain. 17 -20 Intravenous infusion of cetiedil has been shown to shorten the duration of vaso-occlusive crisis. 2' Material and methods The 14 SS patients were in the asymptomatic steady state. Heparinised venous blood was washed through Imugard IG 500 cotton wool (Terumo Corporation, Tokyo, Japan), using 20 mmol/l HEPES buffered saline (HBS) of osmolality 290 mmol/Kg H20 and pH 7 4, to give a suspension of leucocyte free washed erythrocytes. 22 sessed by interference microscopy on 300 oxygenated cells fixed with 125% w/v glutaraldehyde in HBS, using the Bessis classification29 for stomatocytes and echinocytes. Cells whose length was twice their width or those which had angular contours were counted as irreversibly sickled cells (ISC). 30 The extent of haemolysis of the erythrocyte suspensions was assessed from the supernatant haemoglobin concentration, measured spectrophotometrically using tetramethyl benzidine. Significance (two tail) was determined by Wilcoxon's non-parametric signed rank test for paired data.
Results
Calcium loading of sickle cells using A23187 ionophore caused an increase in IF (loss of filterability) after 60 minutes compared with cells in control buffer (fig 1) . As there was considerable variation between patients in the extent to which A23187 increased IF, the effects of oxpentifylline and cetiedil citrate were expressed as pcrcentage change from the IF value after incubation with A23 187 alone (fig 2) . All four concentrations of oxpentifylline significantly improved IF (10 pmol/l, p < 0-05; other concentrations, p <0 01) and caused no change in erythrocyte mor- Cetiedil is a vasodilator" that enhances passive entry of sodium into erythrocytes17 18 and decreases potassium loss via the Gardos pathway after calcium loading. 19 20 Both mechanisms could increase cell water, reduce MCHC and cytoplasmic viscosity, and thus improve erythrocyte deformability. Intravenous cetiedil (0-4 mg/kg body weight) has been shown to shorten the duration of vaso-occlusive crisis,21 and a single infusion at this dose gives a peak plasma concentration of 025 jsmol/l.36 A previous in vitro filtration study of deoxygenated sickle cells showed a beneficial effect of cetiedil at 50-200 jmol/l, with no effect on oxygenated cells.37 The higher sensitivity of our filtration technique detected an effect on oxygenated SS cells treated with ionophore at I pmol/l, the lowest concentration studied. At 100 jimol/l and above, the drug caused substantial cell swelling (stomatoxytosis) and haemolysis, as previously reported.17 18 Oxpentifylline has recently been shown to reduce loss of potassium and therefore water from normal erythrocytes that had been loaded with calcium using the ionophore A23187 or when dehydrated by other ionophores (valinomycin and nystatin)."6 In that study the dehydration was associated with an increase in MCHC, which was partially prevented by oxpentifylline. In the present study oxpentifylline significantly improved the filterability of dehydrated sickle cells at a concentration (1 pmol/l) close to that (0 43 pmol/l) achieved in plasma after ingestion of one 400 mg tablet.38 This contrasts with a concentration of 5 mmol/l required to improve the filterability of normal (AA) cells dehydrated by exposure to this calcium ionophore for 60 minutes. 16 It is difficult to show the action of drugs that change cation flux across membranes when there is no induced change in flux. Previous workers have stressed sickle cells by deoxygenation,37 recurring cycles of deoxygenation-reoxygenation,39 or depletion of adenosine triphosphate and calcium loading '9 to show the in vitro effect of antisickling drugs. Our in vitro model was designed to investigate the protective rheological effect of oxpentifylline and cetiedil when added to sickle cells 15 minutes before they underwent loss of cation and water induced by a calcium ionophore. In the absence of this induced flux neither drug improved the filterability of sickle cells; cetiedil (100 and 500 pmol/l), in fact, impaired filterability further owing to the formation of stomatocytes. Thus the main therapeutic potential of these drugs lies in the prevention of cation and water loss from sickle cells when they are exposed in vivo to stresses such as deoxygenation, calcium loading, low pH or hyperosmolality.
Improving the deformability of dehydrated sickle cells 1185 The rheologically beneficial effect of oxpentifylline on sickle cells was, unlike that of cetiedil, independent of change in cell shape, and neither stomatocytosis nor haemolysis were seen at concentrations up to Further studies of the cation sparing actions of oxpentifylline and cetiedil on the erythrocyte membrane are required, but the demonstration of a beneficial effect on the deformability of stressed sickle cells at a drug concentration of 1 jmol/l indicates the potential of sickle cell "hydrotherapy" for improving blood rheology in this disease.
